educing the high incidence of hypertension-related cardiovascular diseases is an important strategy for the optimal treatment of hypertension. Vascular remodeling, characterized by increased lumen size and thickened media with increased collagen deposition, is a typical feature of end-organ damage from hypertension, contributing to clinical morbidity and mortality. [1] [2] [3] One of the causal factors for vascular remodeling is angiotensin II (Ang II), a key effector of the renin-angiotensin system. Studies have indicated that in addition to its roles in vasoconstriction and retention of sodium and water, causing hypertension, Ang II is also involved in stimulating vascular smooth muscle cell (VSMC) contraction, augmenting cell growth, increasing deposition of extracellular matrix, inducing cell migration, and promoting inflammation and oxidative stress, ultimately leading to vascular hypertrophy, fibrosis, and remodeling. [4] [5] [6] Increased knowledge of the downstream signaling cascades of Ang II-induced hypertension and vascular remodeling is needed if effective clinical interventions are to be developed.
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The cellular repressor of E1A-stimulated genes (CREG) is a novel secreted glycoprotein associated broadly with diverse cellular processes. 7, 8 CREG is ubiquitously expressed in mature tissues and cells in mammals and is expressed at low levels in immature cells, such as pluripotent mouse embryonic stem cells, human embryonic carcinoma cells, and synthetic phenotypic VSMCs. [8] [9] [10] In embryos 9.5 days post-coitum, CREG expression emerges at the beginning of vascular development when vessels comprise only a monolayer of cells. With advanced differentiation, CREG was expressed continuously not only in endomembranes and the vascular tunica media, but also in adventitia until 18.5 days post-coitum. 11 Interestingly, studies of CREG have revealed that CREG levels were greatly reduced in the arteries after vascular injury, whereas forced expression of CREG attenuates proliferation and dedifferentiation of VSMCs, and neointimal formation, 8, [12] [13] [14] [15] implicating in maintaining vascular homeostasis.
Modulation of CREG levels may, therefore, determine the processes of vascular (patho)biology. Previous studies have demonstrated that transcription factor (TF) E2F1 16 and microRNA-31 17 binds directly to CREG promoter and 3′UTR (untranslated region) to repress expression of CREG gene, respectively, and then modulates the VSMC phenotype through the interactions. However, no information is available regarding a role of CREG in Ang II-mediated vascular remodeling. We report here that CREG is a determining factor in the development of vascular remodeling in which Ang II-induced E26 transformation-specific-1 (Ets1) activation plays a critical role in the downregulation of CREG gene expression.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Involvement of CREG in Ang IIMediated Vascular Remodeling
For evaluation of the potential role of CREG as a mediator of vascular remodeling in vivo, Dahl salt-sensitive rats fed a high salt (4% NaCl) diet for 8 weeks developed an increase in medial to lumen ratio and medial area ( Figure I in the onlineonly Data Supplement), a decrease in CREG gene expression, and an increase in vascular local Ang II and aldosterone content as compared with those fed with a normal salt (0.5% NaCl) diet (Figure 1 ). The administration of the ARB (angiotensin II receptor blocker) candesartan (10 mg/kg·per day) significantly inhibited the downregulation of CREG expression while on high salt diet ( Figure 1A and 1B), indicating that high salt-induced increase in local Ang II level might cause CREG downregulation and vascular remodeling in artery tissues.
In Ang II-induced hypertension model, Ang II infusion (400 ng/kg·per minute) led to a predictable increase in plasma and vascular Ang II levels (Figure 2A and 2B) . CREG was markedly detectable in mouse normal aorta. The administration of Ang II resulted in a significant decrease in the level of CREG mRNA from the second day and CREG protein from the third day compared with saline infusion groups ( Figure 2C and 2D). Increased medial to lumen ratio and medial area and deposition of collagen content in the medial layer of thoracic and mesenteric aortas were seen at 7 days and gradually increased in quantity ≤28 days ( 
CREG Deficiency Aggravates Ang II-Induced Vascular Dysfunction
Heterozygous deletion of the CREG gene was found to significantly reduce CREG expression in the aorta. Meanwhile, a reduced expression of CREG was observed in both the CREG +/+ and CREG +/− mouse aortas after Ang II infusion, with a significant reduction from that of CREG +/− mouse aortas ( Figure 3A 
Rescue With Exogenous Recombinant Human CREG Protein Reverses Ang II-Induced Vascular Remodeling
We next evaluated whether exogenous rhCREG (recombinant human CREG) protein could prevent Ang II-mediated pathological remodeling in the aortas implanted with a drug delivery system connected to a mini-osmotic pump. Application of rhCREG protein prevented downregulation of CREG protein expression induced by Ang II in the aortas ( Figure 4B ), although that had no effect on CREG mRNA level ( Figure 4A ). Morphometric analyses confirmed the marked protective effects of rhCREG protein against Ang II-induced vascular remodeling (Figure 4C and 4D; Figures VIII through XA in the online-only Data Supplement), with reduced media to lumen ratio, medial area, and vascular fibrosis in a dose-dependent manner. These findings clearly indicate that rhCREG protein rescued the adverse effects of Ang II on the arteries.
Transcription Factor Ets1-Mediated Repression of CREG Gene Expression by Ang II
Based on the above data demonstrating that CREG is a critical regulator of vascular remodeling in response to Ang II, and Ang II-induced downregulation of CREG gene in arteries plays an important role in regulating vascular remodeling, we, therefore, explored the regulative mechanism of Ang IImediated downregulation of CREG gene expression both in arteries and in VSMCs. First, the promoter-binding TFs profiling plate array was performed in VSMCs with or without Ang II stimulation. Out of 48 TFs, Ets1 and Stat1 were chosen as the TFs most likely to bind to the CREG promoter according to the bio-information analysis (PROMO database, version 8.3 of TRANSFAC; Table) .
Then, a ChIP assay was used to confirm binding of Ets1 and Stat1 to specific binding sites within the CREG promoter using cellular extracts from VSMCs stimulated with Ang II. PCR primers were made for 6 regions of the CREG promoter, denoted ChIP1 through ChIP6. Immunoprecipitation of the protein-DNA cross-linked fragments using Ets1-specific antibody confirmed binding of Ets1 to regions containing the -1179 and -271 Ets1 sites (ChIP3 and ChIP5; Figure 5 ). We also performed a similar ChIP for the TF Stat1 that indicated no binding site of Furthermore, Ets1 expression was detected to increase in a concentration-and time-dependent manner when VSMCs were treated with Ang II (Figure 6A and 6B) . The presence of candesartan blocked the Ang II-induced changes of CREG and Ets1 protein expressions in VSMCs. In contrast, inhibition of the Ang II type 2 receptor did not significantly alter the changes of CREG and Ets1 protein expressions in response to Ang II ( Figure 6C ). Confocal microscopy showed that Ets1 was mainly localized in the cytoplasm under basal conditions, and nucleus translocation of Ets1 was noted with Ang II treatment for 2 hours in VSMCs ( Figure 6D ), an earlier time point than the downregulation of the CREG gene. We then examined whether Ets1 is directly involved in the regulation of CREG gene transcription. VSMCs treated with siRNA directed against Ets1 led to a marked suppression in the decrease of the activity of the CREG luciferase reporter ( Figure 6E ) and CREG gene expression by Ang II (Figure 6F and 6G) . Additionally, transient transfection in VSMCs with the plasmid encoding Ets1 resulted in a decrease in the activity of the CREG luciferase reporter ( Figure 6E ) and the expression of the CREG gene ( Figure 6H ). The dominant negative Ets1 peptide, as an alternative approach toward inhibiting function of Ets1, also inhibited the decrease of CREG in response to Ang II in VSMCs compared with no effect of the mutant Ets1 peptide (Figure 6I and 6J; Figure XC in the online-only Data Supplement). Taken together, these observations suggest that Ets1 plays a primary role in the Ang II-mediated inhibition of CREG gene expression.
Inhibition of Ets1 Prevents Ang II-Induced Vascular Remodeling by Blocking the Reduction of CREG
As shown in Figure 7A , CREG downregulation was significantly blunted in the thoracic aorta of mice treated with the dominant negative Ets1 peptide, whereas the mutant Ets1 peptide did not have this effect ( Figure 7A) . Similarly, the dominant negative Ets1 peptide blunted the increase in aortic medial area, media to lumen ratio, and collagen deposition compared with those treated with saline or the mutant Ets1 peptide ( Figure 7B ; Figure XC in the online-only Data Supplement). These results indicate that the Ets1-mediated decrease in CREG expression observed in the aorta in response to Ang II is attributable, at least in part, to the induction of hypertensive vascular remodeling ( Figure XD in the online-only Data Supplement).
Discussion
The CREG gene, discovered in 1998, is located at Chromosome 1 locus 1q24. 9 Mammalian CREG is a small, 220 amino acid, endosomal/lysosomal glycoprotein implicated in cellular growth and differentiation. [8] [9] [10] 15, [17] [18] [19] Human CREG is 77% identical to mouse CREG and 31% identical to the Drosophila homolog. Previous studies showed that CREG resides in lysosomal compartments and is proteolytically processed by the action of lysosomal cysteine proteinases. 7 In the present study, the results demonstrate, for the first time, an important role of CREG in controlling vascular remodeling in response to Ang II.
Systemic administration of Ang II via continuous infusion is associated with significant vascular remodeling over a period of several weeks. 5, 20, 21 In our study, we demonstrated that Ang II leads to structural changes in the thoracic and mesenteric aorta that are similar to those observed previously, including medial hypertrophy and collagen deposition. Moreover, we also found that CREG expression was downregulated in the arteries of mice with vascular remodeling compared with saline-treated mice. Changes in CREG expression in arteries, prior to initiation of vascular remodeling, may provide information about the pathological status of the artery.
In earlier studies, we reported that the expression of CREG in an injured carotid wall was decreased, and injury-induced CREG downregulation facilitated VSMC dedifferentiation and adventitial fibroblast transformation, as well as cell proliferation, migration, and lesion formation. 8, [12] [13] [14] [15] In this context, CREG may serve as a critical mediator in the maintenance of vascular homeostasis in the process of vascular remodeling. CREG gene ablation in mice causes early embryo lethality. The heterozygous CREG mice with loss of only a single copy of the CREG gene are born at the expected Mendelian ratio and develop into adulthood. CREG +/− mice, of which levels of CREG are 50% to 55% lower than those of wildtype mice, show normal vascular function under basal conditions. However, they are more prone to stress than wild-type mice. We showed an exaggerated hypertensive vascular remodeling response to Ang II in mice with lower levels of CREG, which could be the cumulative outcome of drastically reduced expression of CREG in arteries. In contrast, rescue with exogenous rhCREG protein protected against Ang II-induced vascular remodeling in a dosedependent manner, which agrees with the hypothesis that protective effects may act through the regulation of CREG expression in vascular cells, in particular with regard to the possible direct positive or negative regulation of CREG as a promoter-bound factor.
Available data indicate that several mechanisms could be involved in the regulation of CREG gene. TF E2F1, positioned on the human CREG promoter at -446 and -97 bp from the transcription initiation site, results in repression of CREG promoter activity and mRNA/protein levels. 16 MicroRNA is a type of posttranscriptional regulation of gene expression and may regulate at least 30% of the genes in a cell. 22 We previously showed that miRNA-31 directly binds to CREG 3′UTR and modulates the VSMC phenotype through this interaction. 17 The main purpose of this study was to elucidate the detailed molecular mechanism, whereby Ang II downregulates the expression of the CREG gene in VSMCs. This led to the identification of Ets1 as the major and direct mediator of Ang II-induced inhibitory effect on mouse CREG transcription.
The Ets1 is the founding member of the Ets gene family, whose members share a highly conserved DNA-binding domain GGAA/T sequence and are commonly involved in the regulation of development, inflammation, immunity, differentiation, and proliferation. 23 It has been reported that Ets1 is expressed in endothelial cells and VSMCs in blood vessels and is a critical regulator of Ang II-mediated vascular inflammation and remodeling. 20, 21 Ets1 is induced in VSMCs in response to a variety of stimuli, including Ang II, PDGF (platelet-derived growth factor), thrombin, interleukin-1, and tumor necrosis factor-α. [24] [25] [26] [27] In agreement with previous observations, our study shows that Ang II increases Ets1 expression in a time-and dose-dependent manner in mouse VSMCs, which inversely correlates with the changes seen in CREG, and it also induces Ets1 nucleus translocation, delineating the critical role of Ets1 in the mechanism by which Ang II controls CREG gene expression. Moreover, this notion was confirmed by siRNA-mediated silencing of Ets1, which led to inhibition of Ang II-induced downregulation of CREG levels. Additionally, the involvement of Ets1 in regulating CREG expression was further examined by upregulating Ets1 expression in VSMCs. Increasing the expression level of Ets1 resulted in marked downregulation of CREG mRNA and protein. Taken together, these data demonstrate that the low level of expression of CREG in VSMCs is maintained by Ang II-induced Ets1, providing a rationale for understanding the occurrence and development of vascular remodeling in response to Ang II.
Ets1 has a dual function, acting as both a transcriptional activator and a repressor via association with specific cofactors and in combination with other TFs, depending on promoter context. 28 In most cases, Ets1 positively regulates the expression of its target genes. However, Ets1 also functions as repressor of its target genes, [28] [29] [30] including interleukin-10, cyclin D3, retinoblastoma-associated factor 600, AXL receptor tyrosine kinase, MET tyrosine kinase, β-2-adrenergic receptor, stromal cell-derived factor receptor 1, ATP5G3, 5-tubulin, serine-threonine-kinase 6, and anilin/actin-binding protein. In addition, Ets1 can also suppress gene expression through interacting with repressive factors like EAP1/Daxx, HDAC1, mSin3a, and DNA methyltransferase 3a and 3b. 28 Those molecules could form an Ets1 repressor complex and affect the epigenetic statue of DNA methylation and histone modifications, resulting in an inactive chromatin configuration at Ets1 target gene loci.
Understanding the mechanisms of transcriptional gene regulation involved in vascular homeostasis can provide key insights into potential therapeutic strategies. Our findings demonstrate that CREG is a novel modulator that is involved in the process of Ang II-induced vascular remodeling and further elucidate that the activation of Ets1 activity by Ang II contributes to decreased expression of the CREG gene ( Figure 7G ). These effects, in turn, lead to medial hypertrophy and collagen deposition. This newly discovered relationship between vascular CREG and Ets1 may be informative for the treatment of patients with vascular remodeling associated with Ang II.
